[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_2341 

# __Invasive individual testing__

## Category to which it belongs

* [The challenges in the field of testing and drug development, including limited capacity, slow processes, and the need for improved detection methods, hamper the identification and control of cases.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_134.md)

## Closest similar item

* [Mass testing](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_335.md)
* [Testing](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3393.md)
* [Limited testing and treatment capabilities](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2786.md)
* [Limited diagnostic and screening tests](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2161.md)
* [Screening](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3391.md)
* [Limited diagnostic tests](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2567.md)
* [Widespread testing and contact tracing](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3430.md)
* [Limited access to testing](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2340.md)
* [Limited testing access](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_881.md)
* [Low testing frequency in previously infected individuals](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_864.md)

## Description of the risk

Individual testing methods for COVID-19 require invasive procedures such as nasopharyngeal swabs, which can be uncomfortable and inconvenient.

## Is the risk affecting GBN scales

* [Yes](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_1.md)

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Type of impact of the risk (according to ISO37100)

* [Health and care](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_0.md)

## Type of purpose of the risk (according to ISO37100)

* [Well-being](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_1.md)

## Mitigations of this risk

* [Develop and promote non-invasive testing methods, such as saliva or wastewater-based surveillance, to increase testing uptake.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_3071.md)

## Name of the risk

Decreased willingness to get tested, leading to underreporting of cases and limited knowledge of the true prevalence of the virus.

## Stakeholders who can mitigate this risk

* [Public health officials](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_310.md)
* [Healthcare systems](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_193.md)

## Articles mentionning the risk

* [SARS-CoV-2 Titers in Wastewater Are Higher than Expected from Clinically Confirmed Cases](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_251.md)

## People affected by this risk

* [General population](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_9.md)
* [Individuals with symptoms or high-risk exposures](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_1570.md)

## Technologies linked to the risk

* [Development of non-invasive testing techniques](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1970.md)
* [Improvement of testing accuracy and reliability](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1971.md)

## Property: has_RiskType

* [Health](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_4.md)

